Small Cap Voice

Friendable Inc. (OTC:FDBL) is a mobile technology and marketing company focused on developing and identifying products, services and brand opportunities with mass market potential and scalability.

Friendable published its first mobile application in the Apple App Stores and Google Play stores in 2014, in the social networking and dating category. The Friendable app achieved over 1.5 million downloads, Top 10 worldwide rankings, and has led to celebrity-related marketing opportunities and various relationships with well-known music artists, as well as up-and-coming independent artists.

Friendable has since removed the social dating app from the app stores and has pivoted its business focus to Fan Pass, the livestream artist platform. Launched July 24, 2020, the Fan Pass livestream platform has proven to be invaluable for artists and fans alike as performances shifted from the stage to the screen.

Friendable was founded by brothers Robert A. Rositano Jr. and Dean Rositano who have more than 27 years of experience working together on technology-related ventures.

For more information, visit www.Friendable.com or www.FanPassLive.com.

Business Highlights

Splash Beverage Group continues to accelerate brand growth throughout key markets, both domestic and international.

Company stock uplisted to the NYSE/American Exchange in June 2021

Since the start of 2021, the company has entered into significant distribution agreements with at least seven leading independent US distributors

Began operations on its first acquisition Copa di Vino

Secured distribution for all its brands in China through a deal with American Software Capital targeting a combined market opportunity of more than $64 billion

Announced that its Qplash platform will integrate all its brands to rapidly expand its national market presence

Splash Beverage Group specializes in manufacturing, distribution, sales & marketing of various beverages across multiple channels. SBEV operates in both the non-alcoholic and alcoholic beverage segments which they believe leverages efficiencies and dilutes risk. SBEV believes its business model is unique as it ONLY develops/accelerates brands it perceives to have highly visible pre-existing brand awareness or pure category innovation.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Lloyd Spencer, chairman and CEO of CoroWare. The interview focuses on the development of the Company business model as it transitions to address the global need for efficient, sustainable waste management solutions. The Company will use proven technologies to process organic waste into hydrogen and high-value carbon products for customers in the automotive, aviation, medical and construction industries, as well as supply its Carbon Nanotubes (CNTs) for the next-generation of clean energy transportation.

Recently the company announced it has entered into a Mutual Release and Settlement Agreement with YA Global Investments, L.P. ("YA Global"), an alternative investment manager and provider of specialty financing solutions, based in New Jersey.

"Reaching a final settlement with YA Global is a critically important step that will greatly help CoroWare attract new investors," said Lloyd Spencer, chairman and CEO of CoroWare. "Through this agreement, CoroWare is furthering its plan to produce economically sustainable hydrogen and high-value carbon products and increase long-term shareholder value."

CoroWare Inc. (OTC: COWI), headquartered in Woodinville, Washington, is in the early stage of transitioning into a resource reclamation company that will process organic wastes and generate economically sustainable hydrogen and high-value carbon products.

For more information, please visit www.CoroWare.com.

Dr. Bill Williams, BriaCell’s President and CEO, called into SmallCapVoice.com to discuss the recent news and events for the Company here in the summer of 2021. BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and non-small cell lung cancer. Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer, remains on track to enter the clinic in 2021. In addition, BCTX announced the open recruitment and enrollment of their collaborative clinical study with Incyte. The Phase I/IIa combination study is designed to evaluate BriaCell’s lead candidate, Bria-IMT, with Incyte’s checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer.

“We are thrilled about the prospects of our novel targeted off-the-shelf personalized immunotherapies for patients with advanced prostate cancer, melanoma and lung cancer,” said Dr. Bill Williams, BriaCell’s President & CEO. “Working with our world class scientists and collaborators, we look forward to bring these novel immunotherapies to patients in desperate need of new treatments.”

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

Cannabis Global, Inc. Discusses the Drivers Behind Their Substantial Revenue Growth in Audio Interview with SmallCapVoice.com

AUSTIN, Texas (July 13th, 2021) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Cannabis Global, Inc. (OTC PINK: CBGL), the majority owner of Natural Plant Extract of California, a licensed cannabis manufacturer and distribution company. Arman Tabatabaei, Company CEO, discusses how the Company’s focus on the quality of its ingredients, its pipeline of products, patents and patent applications, as well as its steadfast commitment to being a innovator in the cannabis space is now paying dividends for the company.

The Company recently announced that it expects to report revenue of $940,000, up from $20,000 as reported on the Company's Form 10-Q for the same period one year ago. The drivers behind those numbers are highlighted in this interview.

Speaking with SCV’s Stuart Smith, Tabatabaei described how the Company has taken the product philosophy of doing things differently in the incredibly competitive cannabis space. Rather than introduce a variety of products in various segments, CBGL has taken a different stance. The vision is to only focus on products that will stand out in the marketplace. This has resonated with their target markets. For example, their edible products are based on a simple premise – use only the finest ingredients. Other companies base their edibles on artificial flavors and colors, while CBGL base their products on real fruit purées, natural flavors, and other ingredients that are the best in class.

Tabatabaei discussed how CBGL remains an innovator, “We are especially proud of our first run of diamond Infused pre-rolls. The test actually came out in excess of 45%, but potency isn’t the only measure of a quality product, it’s also taste. In our first product runs, we think we have nailed both and our product reviews have been phenomenal. Relative to other products the market should expect to see from us, we plan to continue our focus on quality through our Northern Lights brand, but we also have developed several high-capacity production techniques that will allow us to offer these products at extremely attractive price points. In that regard, we want to be disruptive to the marketplace relative to both extreme quality of our ingredients and very attractive pricing into the wholesale market,” Tabatabaei told Smith.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with DigiMax Co-Founder and CEO Chris Carl (CSE: DIGI)(OTC: DBKSF) to discuss how the Company’s moves in 2020 and early in 2021 are paying off for the Company in 2021.

DigiMax is a technology company committed to unlocking the potential of disruptive technologies by providing advanced financial, predictive, and cryptocurrency solutions across various verticals. DigiMax is an official IBM Watson partner, and the Company's engineering team has extensive experience in Machine Learning, Neural Language Processing, AI, Big Data and Cryptocurrency technology. The Company recently provided an update about the successful activities being realized at its wholly owned subsidiary, DataNavee Inc.

Dr. Bill Williams, BriaCell’s President and CEO, called into SmallCapVoice.com to discuss the recently announced overall survival (OS) data on its previously disclosed advanced breast cancer patients. These women were treated with BriaCell’s lead candidate Bria-IMT as monotherapy and also in combination with checkpoint inhibitors, including pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.) and Incyte’s retifanlimab (manufactured and provided under a corporate collaboration with Incyte Corporation).

HLA-Typing: Cells with HLA (human leukocyte antigen) molecules on their surface determine and trigger the body’s immune response. BriaCell’s immunotherapy treatment appears most effective when the patient’s HLA-type matches with Bria-IMT, allowing BriaCell to potentially identify patients most likely to respond. HLA-typing is a simple and widely available test.

Tumor Grade: BriaCell has noted clinical benefit in its patients with grade I and grade II tumors, suggesting another subgroup of patients for whom BriaCell’s treatment would be most effective.

Highlighting BriaCell’s Top Responder:

Initially announced on Sep. 19, 2019 and subsequently on Jan. 13, 2020, BriaCell has continued to emphasize this patient’s positive response to BriaCell’s treatment. Prior to BriaCell’s treatment, the patient had received 12 regimens with 16 agents (incl. 13 chemotherapies), yet her condition worsened and included a gruesome orbital tumor that metastasized behind her left eye and caused the eye to bulge from its socket (proptosis). After just six months of BriaCell’s treatment, the orbital tumor had been completely eliminated, and she survived for over 21 months, a significant clinical benefit.

"Women with advanced breast cancer often are fighting a deadly disease that does not respond to currently-available treatments," said Dr. Bill Williams, BriaCell’s President and CEO. "We are pleased to report that our immunotherapy regimen appears to offer clinical benefit for these patients in desperate need of new therapy options."

Deep Green Waste & Recycling, Inc. Discusses its Waste and Recycle Management Services in Audio Interview with SmallCapVoice.com

AUSTIN, Texas (June 15, 2021) -- SmallCapVoice.com (“SCV”) announces the availability of a new interview with Lloyd Spencer, President and CEO of Deep Green Waste & Recycling, Inc. (OTCQB: DGWR), to discuss how the Company’s moves in 2020 are paying off for the Company in 2021.

Deep Green Waste & Recycling, Inc. is a sustainable waste and recycle management services company for commercial customers who recently announced the Letter of Intent (LOI) to acquire an environmental remediation and services company adding another revenue stream for the Company in a market similar to the one they already operate in.

Speaking with SCV’s Stuart Smith, Spencer described the moves made in 2020 and early in 2021 that have built a foundation for future growth with the ability to continue to grow by establishing strategic relationships with institutional investors that offer substantial and longer-term financing solutions. The goal of these financings will be to acquire additional profitable waste and remediation services companies in the Southeast United States.

“The Company restarted its business last year. In August of 2020 we announced a an LOI to acquire Amwaste, Inc. We completed that acquisition in March of 2021. Now, Amwaste is up and going with DGWR and offering services to communities in Georgia like Brunswick and St. Simon’s Island. The Company is profitable and growing and it is important to note that this is a business that has been in operations well over ten years.” He stated. “If you look at our 10Q you will see that we recorded our first quarter of revenues with Amwaste and you will see the growth. You will also see in that 10Q that we were able to remove the Company's "shell risk" designation from OTC Markets.”

The CEO then expanded on the LOI to acquire an environmental remediation and services Deep Green signed.

“This is a really exciting new part of the business, and we think this is going to grow the Company quickly in a rapidly growing industry.” he said. “In the environmental services business you are looking at businesses or homes that are looking to remove asbestos or remove lead paint and other hazardous materials.”

The interview also highlighted DGWR’s accelerated path toward revenue and profitability with the infusion of new capital into the Company allowing it to grow the operations of Amwaste through the hiring of additional people and purchasing additional trucks and containers allowing Amwaste to serve additional communities. We believe that this capital can grow the operations of Amwatse by 30% to 50%.

“One of the nice things with Amwaste, is that we’re not having to go out and create a customer base, but we’re building on top of existing customer bases,” Spencer told Smith. “In fact, we are already finding that we are having difficulty keeping up with demand and that is a wonderful problem to have that is entirely addressable.”

Spencer concluded the interview by explaining how DGWR will experience another “leap of growth” with the completion of the acquisition for the recently signed LOI.

“Not only are we focused on growing organically with the operations of Amwaste, but we will also be growing through acquisition with the addition of the environmental remediation and services company here in 2021.”

USAQ Chief Executive Officer Troy Grogan discusses the recently announced co-promotion agreement with ENP Network, the largest web-based services provider to the nurse practitioner (NP) community and nurse practitioner associations with over 260,000 members. In addition, USAQ products, AllergiEnd®’s allergy diagnostic and allergen immunotherapy products will be featured at the upcoming University of Miami’s Miller School of Medicine Allergy Diagnostics and Allergen Immunotherapy Virtual CME event on June 26, 2021.

“We are very excited to be partnering with ENP Network which will further expand our independent medical provider customer network, leveraging ENP’s extensive network and industry knowledge of the nurse practitioner sector. Our AllergiEnd® allergy diagnostic and allergen immunotherapy products are well suited to provide nurse practitioners with enhanced chronic disease management, preventive solutions and value-based digital tools to evaluate and treat their patients. These procedures are also reimbursable under existing government and private insurance programs, providing NPs with an additional revenue stream for their practice. We look forward to announcing additional industry partnerships as we continue to execute on our growth strategy,” stated USAQ Chief Executive Officer Troy Grogan.

Business Warrior Management Discusses Dramatic Jump in March Revenues in Audio Interview with SmallCapVoice.com

Business Warrior previously reported that its March revenues increased over 350% compared to February. However, as the accounting for the month was closed, the actual revenue growth exceeded that estimate by reaching over 412% revenue growth. Additionally, the company is reporting that the positive momentum continued through April and May, which will result in the company's strongest quarter ever.

Business Warrior's goal is to help its business subscribers determine what's preventing them from getting more customers, guide them to solve the problems identified, and propel their marketing campaigns forward to reach a clear return on investment. Its business model specializes in small local businesses or medium sized companies looking to scale up.

"Every business owner wants to know if their marketing dollars are giving them a return on their investment (ROI), but it remains a big, unknown answer to most of them. Our software identifies the gaps for their business, helps them solve those gaps and then we provide the solutions to get them more customers," said Business Warrior CEO, Rhett Doolittle.